Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how safe it is to give patients a shot that has a
mixture of a vaccine and dendritic cells (DCs), a special kind of immune cell, and how safe
it is to give a shot of the vaccine alone.
Current HIV vaccines have not been strong enough to give good immune responses. Research has
shown that the immune response to a vaccine delivered by DCs is greater than the response
without DC delivery. A5130 is a study that seeks to give good delivery of the vaccine to
important immune cells of the body.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)